The SynCardia freedom driver: A portable driver for discharge home with the total artificial heart.

摘要

In March 2010, the U.S. Food and Drug Administration approved the SynCardia Freedom Driver (SynCardia Systems Inc, Tucson, AZ) for an investigational device exemption study. We report the first use in our institution of the SynCardia temporary total artificial heart (TAH-t) Freedom Driver in a 41-year-old African American man (body surface area, 2.1 m2) 12 years after he underwent orthotopic heart transplant for anti-cardiolipin antibody-related throm-botic infarction.The patient presented with irreversible cardiogenic shock, and the TAH-t was implanted.1 Because of high antibody levels, he was hospitalized without a suitable donor for 83 weeks until he became the first patient in our institution to receive Freedom Driver implantation.